Variables | ACE2 | P-value | |
---|---|---|---|
Higher (> 14.78) | Lower (< 14.78) | ||
N = 56 | N = 55 | ||
Mean-Age (years) | 52.89 | 50.2 | |
ACE2 (ng/mL) | 21.23 | 9.71 | |
Chemotherapy | |||
Chemotherapy-resistant | 36(64.29%) | 21(38.18%) | 0.0059 |
Chemotherapy-sensitive | 20(35.71%) | 34(61.81%) | |
Grade | |||
I | 11(19.64%) | 21(38.18%) | 0.0311 |
II–III | 45(80.36%) | 34(61.82%) | |
T | |||
T1 | 9(16.07%) | 20(36.36%) | 0.0040 |
T2–T3 | 41(73.21%) | 24(43.64%) | |
Tx | 2(3.57%) | 11(20.00%) | |
N | |||
N0 | 19(33.93%) | 28(3.63%) | 0.0700 |
N1–N2–N3 | 37(66.07%) | 27(96.37%) | |
M | |||
M0 | 10(17.86%) | 11(20.00%) | 0.0077 |
M1 | 36(64.29%) | 9(16.36%) | |
MX | 10(17.86%) | 35(63.63%) | |
Surgery | |||
Yes | 33 (58.93%) | 15 (27.27%) | 0.0008 |
No | 23 (41.07%) | 40 (72.72%) | |
Recurrence | |||
Yes | 0 (0%) | 1 (1.82%) | 0.3108 |
No | 56 (100%) | 54 (98.18%) | |
Metastasis | |||
Yes | 6 (10.71%) | 23 (41.82%) | 0.0002 |
No | 50 (89.29%) | 32 (58.18%) |